Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
Unusual Whales
The NMPA has approved the supplemental application for the use of Toripalimab in combination with chemotherapy as a perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC. This decision allows for the treatment to be used in patients with these specific stages of non-small cell lung cancer.
